enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Biogen-UCB's lupus drug meets main goal of late-stage trial - AOL

   www.aol.com/news/biogen-ucbs-lupus-drug-meets...

   The drug is being tested in patients with the most common form of lupus, systemic lupus erythematosus, where the patient's immune system attacks the body's own tissues and potentially leads to ...

3. AstraZeneca lupus drug shows promise after set-back last year

   www.aol.com/news/astrazeneca-lupus-drug-meets...

   The British drugmaker said anifrolumab under the TULIP 2 program helped patients with systemic lupus erythematosus, commonly known as SLE. The drug had failed to meet its main goal in the final ...

4. Anifrolumab - Wikipedia

   en.wikipedia.org/wiki/Anifrolumab

   Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. [5] [7] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.

5. Litifilimab - Wikipedia

   en.wikipedia.org/wiki/Litifilimab

   Litifilimab is an investigational drug being evaluated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. It is an anti- BDCA2 monocolonal antibody. [ 1 ] [ 2 ] [ 3 ]

6. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.

7. Biogen Gains Momentum With Positive Lupus Drug Results ... - AOL

   www.aol.com/finance/biogen-gains-momentum...

   On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus ...

8. Efavaleukin alfa - Wikipedia

   en.wikipedia.org/wiki/Efavaleukin_alfa

   Efavaleukin alfa is an experimental drug that works as an interleukin-2 "mutein Fc fusion protein that preferentially binds the high-affinity IL-2 receptor alpha chain to selectively promote Treg expansion". [1] It is developed to treat systemic lupus erythematosus (SLE). [2] [3] [4]

9. Roivant Sciences' lupus drug fails to reduce symptoms in mid ...

   www.aol.com/news/roivant-sciences-lupus-drug...

   The oral drug, brepocitinib, did not meet the primary study goal of reduction in disease activity at week 52 in patients of SLE, in which the immune system that normally helps protect the body ...